Pharma


  • FDA headquarters sign
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Prasad’s FDA appointment pressures cell and gene therapy stocks

    A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.

    By Ben Fidler • May 7, 2025
  • red and blue pill full of social media icons against yellow backdrop
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    With TV ads under threat, here’s how pharma can leverage social media

    RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.

    By May 7, 2025
  • clinical trial diversity Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • Joaquin Duato
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst

    Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

    By May 6, 2025
  • flask lab
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After an up and down year, pharma’s R&D landscape is shifting again

    While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.

    By Kelly Bilodeau • May 5, 2025
  • Eli Lilly CEO Dave Ricks Speaks At The Economic Club Of New York
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    With compounders out of the way, Lilly and Novo go after each other

    The two obesity leaders are pulling on all levers to stay on top of the market.

    By May 5, 2025
  • lab rat
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Is pharma ready to let go of animal testing?

    Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.  

    By May 2, 2025
  • A wall bearing the Johnson & Johnson logo is seen outside of an office building.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J scores FDA OK for immune drug touted as future blockbuster

    The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.

    By Ned Pagliarulo • May 1, 2025
  • Close-up on a scientist using a mobile app on a digital tablet while working at the laboratory
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.

    Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding. 

    By May 1, 2025
  • Makary
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    Is the FDA headed for a major reorganization?

    A leaked document revealed details about changes that could impact how the agency operates, but recent comments from FDA Commissioner Dr. Marty Makary have muddied the picture. 

    By April 30, 2025
  • FDA
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA’s job cuts paint mixed picture for drugmakers’ R&D plans

    After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

    By April 28, 2025
  • Bottles of Bristol Myers Squibb's Cobenfy, a new drug for schizophrenia, are arranged in this photo illustration.
    Image attribution tooltip
    Permission granted by Bristol Myers Squibb
    Image attribution tooltip

    Will Cobenfy’s clinical stumble derail a once-predicted rise?

    BMS hopes to broaden the applications for the new schizophrenia drug into areas such as Alzheimer’s disease.

    By Kelly Bilodeau • April 28, 2025
  • President Donald Trump speaks in the Oval Office of the White House on April 7, 2025.
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    Trump reveals pharma reform priorities in drug pricing executive order

    The order takes aim at fixing the IRA’s “pill penalty,” as well as PBM reform and other attempts to lower drug prices.  

    By April 23, 2025
  • A large group of dosing pens for subcutaneous injection of anti-obesity medication piled in a heap.
    Image attribution tooltip
    aprott via Getty Images
    Image attribution tooltip

    Beyond the drug: Closing the knowledge gap for injectable diabetes meds

    As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most out of injectable drugs. 

    By April 22, 2025
  • A picture of a man tied to a COVID-19 virus
    Image attribution tooltip
    wildpixel via Getty Images
    Image attribution tooltip

    Genetic breakthroughs could point pharma to a long COVID drug

    The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.

    By Kelly Bilodeau • April 22, 2025
  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Can anything threaten Novo and Lilly’s obesity market dominance?

    Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

    By April 21, 2025
  • beaker shelved
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    How a scrapped Pfizer drug became a winner for SpringWorks

    SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

    By Alexandra Pecci • April 21, 2025
  • layoffs
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Deep Dive

    HHS layoffs may be illegal, legal experts say

    The federal health department sidestepped normal procedures as it laid off 10,000 employees, according to sources. One union has already filed an internal complaint, while at least two law firms are exploring suits.

    By Rebecca Pifer • April 17, 2025
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Sedat Suna via Getty Images
    Image attribution tooltip

    Novartis scores NFL deal to tackle health outcomes

    The non-traditional marketing approach comes amid a potential crackdown on TV drug ads. 

    By April 17, 2025
  • Downtown Raleigh, North Carolina, skyline with a sunset
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub

    Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments. 

    By Alexandra Pecci • April 16, 2025
  • UnitedHealthCare sign
    Image attribution tooltip
    Stephen Maturen via Getty Images
    Image attribution tooltip

    The fallout from UnitedHealth’s CEO slaying

    Brian Thompson’s murder has raised questions about the cost of U.S. healthcare, embroiling insurers, drugmakers and PBMs in a battle for the future of the industry.

    By PharmaVoice staff • April 15, 2025
  • Tariff pharma
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model

    Major changes to the dynamics of the pharmaceutical ecosystem are making executive decisions even tougher.

    By April 14, 2025
  • pharma manufacturing concept
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s US manufacturing moment: Where companies are making the biggest moves

    The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.

    By April 11, 2025
  • President Donald Trump displays a chart showcasing coming tariff rates at the White House on April 2, 2025.
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip

    Trump’s tariff tirade and sudden calm keep Big Pharma on its toes

    A wild ride in an escalating trade war has torn at Big Pharma’s shares while global markets flag in the back-and-forth winds.

    By April 10, 2025
  • A person looks through a pipette while working at a laboratory bench.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip

    US risks losing biotech edge to China, report warns

    “There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.

    By Ned Pagliarulo • April 9, 2025
  • Contemporary artistic collage depicting hands holding binoculars against a blue background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Big Pharma is rewriting the R&D playbook to account for seismic shifts in the investment landscape

    The top 20 pharma companies are focusing on novel drugs, innovative dealmaking and playing to their strengths to bolster R&D ROI.

    By Alexandra Pecci • April 9, 2025